Osteogenesis imperfecta is a heterogeneous group of collagen type 1 defects. The resulting fragile bone with increased risk of fractures and deformity is the primary orthopaedic challenge. Surgical treatment is aimed at reducing the risk of fracture, correcting deformity and improving ambulatory status. Management of the growing child with extensible intramedullary device was introduced in the 1960’s by Bailey and Dubow. Since then a number of different nails have been used. The current report presents our experience with the Fassier-Duval intramedullary nail in the first ten patients.
Median follow-up was 2 years and 3 months (Range 1 – 4 years and 3 month).
5 operations were reoperations due to complications. All of these were in femora. 5 patients had a fracture despite the nail. 3 were reoperated due to bending or perforation of the nail. 2 were treated conservatively. All 5 healed uneventfully. 1 patient was reoperated 3 times. First due to migration of the nail, secondly failure of the nail to elongate and thirdly because of a fracture with bending of the nail. There were no infections, neurological- or vascular damage. At follow-up 6 patients were walking without any aid. 2 were mobilised with aids. 2 were mobilised in wheelchair. No radiographic evidence of growth arrest has been noted secondary to the crossing of the epiphysealplate by the nails.
In the litterature patients suffering Mb. Scheuermann (MS) have been reported to experience more back pain and other back related constrains compared to subjects matched for age and sex. We have been unable to find publications on health-related quality of life by SF-12 or SF-36 in MS. The aim of the present study was to compare health-related quality of life status in MS to the background population.
The aim of the present study was to compare health-related quality of life in CTEV to a background population.
80 reported to have CTEV and the remaining 29,516 were used as controls.
The self-reported prevalence of CTEV was 0.0027 (95% confidence interval 0.0022–0.0034). 80 reported to have CTEV and the remaining 29,516 were used as controls. In the CTEV group SF-12 PCSmean was 50.18 (SD 11.19) vs 53.09 (SD 8.11) in the controls. p<
0.0007. In the CTEV group SF-12 MCSmean was 50.58 (SD 10.52) vs 51.78 (SD 8.47) in the controls. NS.